



Wilsons Drug & Device Conference



Healing. Redefined.

October 26, 2023

This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. PolyNovo Limited makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. PolyNovo and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, or contained in or derived from, or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of PolyNovo. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by PolyNovo or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

NovoSorb[®]

Genius technology

Underserved market

Capital efficient **Growth** and
Scaling

Innovation driven out of frustration with the Existing Standard of Care

2002

Bali Bombing kills 202 and critically injures 209. Australian survivors were repatriated to major Burns units for treatment. Large, delayed and colonized wounds required dermal substitutes, but the existing SOC carried risk of infection and rejection. Prof. John Greenwood (Burns Unit, Royal Adelaide Hospital) sought a synthetic alternative



2004

The CSIRO developed a family of polymers -- synthetic material that could safely biodegrade and be metabolised by the human body -- for use in implantable medical devices. CSIRO/PolyNovo collaboration with Prof. John Greenwood results in development of NovoSorb® BTM

2008: PolyNovo acquired by a ASX listed company; pre-clinical studies and factory established in Port Melbourne.



2013

First patient treated with NovoSorb BTM.

2015

NovoSorb BTM: US 510(k) clearance

2018

NovoSorb BTM: Australian TGA registration, India market authorization

2019

NovoSorb BTM: Receives European CE Mark and US, FDA Breakthrough Device Designation

2021

BARDA ,US FDA partnership for Burns Pivotal trial

2022

NovoSorb MTX: US 510(K) clearance

2023

In 27 markets globally



NovoSorb®: Simple. Elegant. Transformative

Macro to Micro wounds:

NovoSorb BTM's matrix organizes a large wound (macrowound) into a series of interconnected small wounds (microwounds). The body easily heals small wounds, promoting organized, regenerative healing.

- Biocompatible
- Resorbable

Optimized Regenerative Healing






- 100% synthetic, maintains integrity over time and resistant to shear forces.
- Clinically shown to be robust in presence of infection.
- Flexible, allowing clinicians to skin graft at their convenience, in stages or all at once.
- Virtually unlimited in its supply or consistency unlike biologics.
- Used by a variety of Surgeons including Plastic, Reconstructive, Trauma and General

Minimizes scarring. Restores form and function.


Robust IP Portfolio

PolyNovo has obtained IP Protection for its 10 Patent families (incl. 61 patents & 28 patent applications) in a broad range of countries including commercial destinations. These incl. protection for compositions of matter, as well as their general & specific medical use in applications including stents, orthopedic repair, burns & wound repair, hernia, diabetic ulcer & breast reconstruction. The patents and applications are fully owned by PolyNovo, providing protection for company's technologies until as far out as **2038**.



Disciplined Execution

Yielding Strong Business Results and Redefining the Standard of Care




* Seeking alliances


US FDA has cleared NovoSorb BTM wound dressing for management of wounds including; partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic and vascular ulcers, surgical wounds (donor sites/grafts, post Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second degree burns and skin tears) and draining wounds

Where are we today?


Total Employees



Customers (Hospitals)



Total Revenue A\$




➡ Team expansion ➡ New applications

ANZ ➡ U.S. ➡ UK/I ➡ Germany ➡ Canada ➡ Hong Kong ➡ India ➡ Spain ➡ France ➡ **Japan** ➡ **China**

NovoSorb® Will Disrupt Several Attractive Addressable Markets

POLYNOVO FOCUS


Trauma (P&R)
Global incidence:
78.2 MM



Burns (Deep dermal/FT/PT/ST)
Global incidence:
8.9 MM

WORKING WITH ALLIANCES


Hernia/other reconstruction
Global procedures:
8.9 MM



Source : Global Data, Zion reports, 2021, WHO, Government sources
M – 000; MM – 000,000; B – Billion

Global Strategy on a Page:

Focused on Burns & Trauma – Working with alliances in adjacencies



PolyNovo Focus	
Burns and Trauma	US, entering Japan, China
Alliance Potential	
Hernia, Abdominal Wall Reconstruction	
Breast Reconstruction, Augmentation, Aesthetics	
Orthobiologics	
Transformational M&A possibilities	
Plastic and Reconstructive Surgery oriented businesses	

An Exciting Future,

Uniquely situated to drive Global leadership and impact

- **Genius Technology:** Product to Procedure & Platform
- **Underserved market :** From 800m to 7.2B people
- **Committed to Capital Efficient Growth & Scaling**


Purpose driven, Engaged organization

- Building **Global Organization, Processes** and **Technology** to enable scale

Next Generation Reconstructive Option

- **Customers** helping us drive **adoption curve** and **market development**
- Building sustainable **partnerships** will help **amplify impact** beyond our core focus areas

**NovoSorb BTM publications
(cumulative)**





Thank you